阿帕替尼及替吉奥治疗晚期胃癌二线化疗失败的疗效观察

Efficacy of Apatinib and S1 in the Treatment of Advanced Gastric Cancer After Failure of Second-Line Chemotherapy

目的研究阿帕替尼治疗二线化疗失败后晚期胃癌患者的疗效和不良反应。方法回顾性分析2016年10月至2017年12月期间本院收治的62例二线化疗失败的晚期胃癌患者,根据用药不同分成试验组(n=31)和对照组(n=31),试验组使用甲磺酸阿帕替尼治疗,对照组使用替吉奥(SI)治疗,对比两种药物的疗效及不良反应。结果试验组和对照组在治疗总有效率、治疗一年后生存率以及腹泻、手足综合征、骨髓抑制、蛋白尿以及高血压发生率上,差异有统计学意义(P<0.05)。结论阿帕替尼三线治疗晚期胃癌的疗效较替吉奥高,且不良反应可控、耐受性良好。

Objective To investigate the clinical effects and adverse events of apatinib in patients with advanced gastric cancer. Methods A retrospective analysis of 62 patients with advanced gastric cancer suffering second-line chemotherapy failure is made from October 2016 to December 2017 admitted to the hospital, they were divided into control group(n =31) and experimental group(n =31) according to the treatment scheme. The patients in control group were given the S1 treatment, while the patients in experimental group were treated with mesylate apatinib treatment. the clinical effects and adverse reactions of the two drugs were compared. Results There was a statistically significant difference between the experimental group and the control group in the overall response rate, the survival rate after one year of treatment, and the incidence of diarrhea, hand-foot syndrome, myelosuppression, proteinuria and hypertension(P < 0.05). Conclusion The efficacy of apatinib in the treatment of advanced gastric cancer suffering more than second-line chemotherapy failure is higher than that of S1, with controllable adverse reactions and good tolerance.